Practical Guidance for collaborative interventions
Practical Guidance for collaborative interventions
Putting Asia’s HIV response back on track
UNAIDS/10.03E / JC1767E (English original, March 2010) ISBN 978 92 9 173849 6
Science / People / Progress
Accessed: 12.11.2019
Par ses propriétés thérapeutiques, le médicament permet aux professionnels de santé
ainsi quaux pouvoirs publics dassurer la santé des populations. De ce fait, sa disponibilité et
son efficacité sont essentielles et sont le résultat dun circuit complexe (de sa fabrication... à sa
destruction en passant par sa distribution).
Laccessibilité au médicament est un élément déterminant de toute politique de santé.
Elle est garantie par la politique pharmaceutique de chaque pays qui vise à rendre le
médicament disponible pour tous, sur lensemble du territoire (accessibilité géographique), à
tout moment (accessibilité physique), à un prix abordable (accessibilité financière) et en
garantissant son efficacité et sa qualité (accessibilité qualitative
more
Agodokpessi et al. Journal of Pharmaceutical Policy and Practice (2015) 8:12DOI 10.1186/s40545-015-0033-7
Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated
the operation of the RDF and assessed whether there was interruption of supply of asthma me...dicine from 2008 to
2013.
more
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ...results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
3rd Edition – July 2017
www.msfaccess.org
16 January 2008
Global Health Advocacy and Activism Department of Global Health, George Washington University
Strengthening Community responses to HIv Treatment and Prevention